Traders should view this as a strong validation of Certara's technology platform, likely to enhance commercial credibility and drive adoption across biopharma clients. Monitor for follow-on announcements regarding new client engagements or expanded use of Simcyp in other NDAs.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 3 $7.24entry
- T+1 · 9mo ago +1.52%α +0.76% · $7.35
- T+5 · 8mo ago −4.28%α −3.80% · $6.93
- T+20 · 8mo ago −21.27%α −16.87% · $5.70
- T+60 · 6mo ago −26.11%α −36.42% · $5.35
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Certara announced that its Simcyp® Simulator was used to support the FDA's acceptance of PBPK modeling in lieu of clinical studies for the approval of asciminib (Scemblix®), a first-in-class treatment for Chronic Myeloid Leukemia. This marks a significant regulatory validation of Certara's model-informed drug development technology, highlighting its ability to replace at least ten clinical pharmacology studies and streamline the NDA process.
Key Facts
- FDA accepted PBPK modeling via Certara's Simcyp Simulator in lieu of clinical studies for asciminib (Scemblix®) NDA approval.
- Modeling replaced at least ten dedicated clinical pharmacology studies.
- Asciminib is a first-in-class allosteric inhibitor for Chronic Myeloid Leukemia (CML).
- Simcyp's modeling supported dosing regimens and drug interaction profiles across diverse populations.
- Novartis, a Simcyp Consortium member, led the modeling work in collaboration with Certara.
Financial Impact
Significant long-term revenue potential as regulatory acceptance strengthens demand for Certara’s biosimulation tools; validation could lead to broader adoption and expanded contracts.
Risk Factors
- Revenue impact may be delayed as adoption cycles in biopharma are long.
- Success depends on continued regulatory acceptance beyond this single case.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3248265 |
Track record
14 reports on CERT
3 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +51.56% at T+60 after the Aug 15, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 9, 20267d ago Institutional Cluster Mixed 3/10 Entry $12.22 to $12.13 Now $11.39 −6.79% ▼ −0.78% −0.41% vs SPY
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $12.18 to $12.05 Now $11.39 −6.49% ▼ −1.07% −1.38% vs SPY
- Aug 15, 202613w ago Institutional Cluster Bullish 5/10 Entry $8.00 to $8.01 Now $11.39 +42.38% ▲ +0.13% +0.80% vs SPY
- Aug 4, 202614w ago 8-K Neutral 2/10 Entry $7.80 to $8.01 Now $11.39 +46.03% ▲ +2.69% +2.89% vs SPY
- Jul 15, 202617w ago Press Release Neutral 1/10 Entry $7.28 to $6.93 Now $11.39 +56.46% ▼ −4.81% −3.82% vs SPY
- Jun 11, 202622w ago Institutional Cluster Bearish 6/10 Entry $5.27 to $5.20 Now $11.39 −116.13% ▲ +1.33% +1.87% vs SPY
- May 11, 202627w ago 8-K Bearish 6/10 No price data
- May 11, 202627w ago Press Release Bearish 7/10 Entry $5.13 to $5.09 Now $11.39 −122.03% ▲ +0.78% +0.64% vs SPY
- Apr 22, 202629w ago 8-K / PRESS-RELEASE Bullish 7/10 Entry $6.38 to $6.00 Now $11.39 +78.53% ▼ −5.96% −5.56% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers